                                                   Design
                                                   • Single arm, open label
                                                   • 22 patients
    Phase 1b in Moderate to Severe                 • Oral, once daily dose for 28 days
      Atopic Dermatitis Patients                   • 14-day follow-up after dosing completed

Baseline entry criteria:
• Adult, moderate to severe AD patients            Dosing
                                                   • Two sequential dose cohorts
    EASI           ≥16
                                                      • 100 mg (10 patients)
    vIGA-AD        ≥3
                                                      • 200 mg (12 patients)
    PPNRS          ≥4
    BSA            ≥10%
• Documented TCS (Topical Corticosteroid)          Endpoints
  failure for AD
                                                   • Safety
• Prior biologics allowed, after washout, if       • Pharmacokinetics
  patient has responded to treatment               • STAT6 degradation
• Concurrent medications for AD not                • Type 2 biomarkers in blood, skin lesions and lung
  permitted                                        • Clinical activity (EASI, PPNRS, vIGA-AD, patient-
                                                     reported outcomes)                                  24
                                               .
